Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 2/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | SCD | O00767 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 4/20 | 0.30 |
| ▸ | DRD2 | P14416 | 3/20 | 0.30 |
| ▸ | HTR1D | P28221 | 3/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14943589 | 0.74 | CYP1A2 (0.35) | — | |
| SCHEMBL14942558 | 0.71 | KMT2A (0.32) | RAB9AALDH1A1MAPTNPSR1MTOR | |
| SCHEMBL2895873 | 0.71 | BPTF (0.43) | RAB9AALDH1A1MAPTNPSR1MTOR | |
| SCHEMBL10313342 | 0.69 | ESR2 (0.38) | OXTRAVPR1ARAB9ASCDDRD3 | |
| SCHEMBL14576445 | 0.66 | P2RX7 (0.37) | ALDH1A1PTGS2DRD3DRD2HTR1D | |
| SCHEMBL2892066 | 0.62 | KMT2A (0.47) | ALDH1A1MAPT | |
| SCHEMBL31180618 | 0.62 | OXTR (0.38) | OXTRAVPR1ARAB9AALDH1A1MAPT | |
| SCHEMBL8340628 | 0.62 | — | — | |
| SCHEMBL782655 | 0.61 | ALDH1A1 (0.36) | OXTRAVPR1ARAB9AALDH1A1MAPT | |
| SCHEMBL8144794 | 0.60 | RAB9A (0.42) | OXTRAVPR1ARAB9AALDH1A1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040928-A1 | NITROGEN HETEROCYCLE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2013-02-14 | — | — | US | disclosed |
| US-20130040928-A1 | NITROGEN HETEROCYCLE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040928-A1 | NITROGEN HETEROCYCLE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN HUMAN THERAPEUTICS | PRMT1, NNMT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | OXTR 174/4885AVPR1A 306/4885RAB9A 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.